Svenningsson A, Andersson M, Olsson T
Neurologiska kliniken, Karolinska sjukhuset, Stockholm.
Lakartidningen. 1998 Dec 2;95(49):5623-7, 5630.
Multiple sclerosis (MS) is a demyelinating, central nervous system disease, of putative autoimmune pathogenesis. Although no effective pharmacological therapy has been available for this often disabling disease until recently, several studies have now confirmed that subcutaneous or intramuscular administration of beta-interferon may reduce the frequency and severity of relapses in relapsing MS, and may also inhibit disease progression. Studies are under way to determine the possible efficacy of beta-interferon during the progressive phase of the disease. Three beta-interferon formulations are currently available in Sweden. Another drug, glatiramer acetate, also shown to have some effect on the disease course, is expected to be registered for use in Sweden shortly.
多发性硬化症（MS）是一种脱髓鞘性中枢神经系统疾病，其发病机制推测为自身免疫性。尽管直到最近对于这种常常导致残疾的疾病尚无有效的药物治疗方法，但现在多项研究已证实，皮下或肌肉注射β-干扰素可降低复发型MS的复发频率和严重程度，还可能抑制疾病进展。目前正在进行研究以确定β-干扰素在疾病进展期可能的疗效。瑞典目前有三种β-干扰素制剂。另一种药物醋酸格拉替雷，也已显示对病程有一定作用，预计不久将在瑞典注册使用。
